Assessing Pharmacists' Preferences towards Efficacy Attributes of Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis

Introduction: Hospital pharmacists are increasingly playing a critical role in the care of patients with multiple sclerosis (MS). However, little is known about their preferences and perspectives towards different attributes of disease-modifying therapies (DMTs). The objective of this research was t...

Descripción completa

Detalles Bibliográficos
Autores: Martínez-López, Icíar, Maurino, Jorge, Sanmartin-Fenollera, Patricia, Ontanon-Nasarre, Ana, Santiago-Perez, Alejandro, Moya-Carmona, Isabel, Gustavo Garcia-Collado, Carlos, Fernandez-Del Olmo, Raquel, Garcia-Arcelay, Elena, Sarmiento, Monica, Carreno, Agata, Perez-Encinas, Montserrat
Tipo de recurso: artículo
Fecha de publicación:2020
País:España
Institución:Conselleria de Salut i Consum del Govern de les Illes Balears
Repositorio:Docusalut
Idioma:inglés
OAI Identifier:oai:docusalut.com:20.500.13003/10487
Acceso en línea:https://hdl.handle.net/20.500.13003/10487
Access Level:acceso abierto
Palabra clave:multiple sclerosis
pharmacist
preferences
disease-modifying therapy
disease progression
id ES_b90bf9aa8d5e81de3ce5a8aa856fc74f
oai_identifier_str oai:docusalut.com:20.500.13003/10487
network_acronym_str ES
network_name_str España
repository_id_str
spelling Assessing Pharmacists' Preferences towards Efficacy Attributes of Disease-Modifying Therapies in Relapsing-Remitting Multiple SclerosisMartínez-López, IcíarMaurino, JorgeSanmartin-Fenollera, PatriciaOntanon-Nasarre, AnaSantiago-Perez, AlejandroMoya-Carmona, IsabelGustavo Garcia-Collado, CarlosFernandez-Del Olmo, RaquelGarcia-Arcelay, ElenaSarmiento, MonicaCarreno, AgataPerez-Encinas, Montserratmultiple sclerosispharmacistpreferencesdisease-modifying therapydisease progressionIntroduction: Hospital pharmacists are increasingly playing a critical role in the care of patients with multiple sclerosis (MS). However, little is known about their preferences and perspectives towards different attributes of disease-modifying therapies (DMTs). The objective of this research was to assess pharmacists ' preferences for DMT efficacy attributes. Methods: A multicenter, non-interventional, cross-sectional, web-based study was conducted. Preventing relapses, delaying disease progression, controlling radiological activity, and preserving health-related quality of life (HRQoL) and cognition were the attributes selected based on a literature review and a focus group with six hospital pharmacists. Conjoint analysis was used to determine preferences in eight hypothetical treatment scenarios, combining different levels of each attribute and ranking them from most to least preferred. Results: Sixty-five hospital pharmacists completed the study (mean age: 43.5 +/- 7.8 years, 63.1% female, mean years of professional experience: 16.1 +/- 7.4 years). Participants placed the greatest preference on delaying disease progression (35.7%) and preserving HRQoL (21.6%) and cognition (21.6%). Importance was consistent in all groups of pharmacists stratified according to demographic characteristics, experience, research background, and volume of patients seen per year. Conclusions: Understanding which treatment characteristics are meaningful to hospital pharmacists may help to enhance their synergistic role in the multidisciplinary management of patients with MS.MDPI20202020-06-0120202020-06-01research articlehttp://purl.org/coar/resource_type/c_2df8fbb1info:eu-repo/semantics/articleapplication/pdfhttps://hdl.handle.net/20.500.13003/10487reponame:Docusalutinstname:Conselleria de Salut i Consum del Govern de les Illes BalearsInglésengopen accesshttp://purl.org/coar/access_right/c_abf2Attribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:docusalut.com:20.500.13003/104872026-06-22T12:44:07Z
dc.title.none.fl_str_mv Assessing Pharmacists' Preferences towards Efficacy Attributes of Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis
title Assessing Pharmacists' Preferences towards Efficacy Attributes of Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis
spellingShingle Assessing Pharmacists' Preferences towards Efficacy Attributes of Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis
Martínez-López, Icíar
multiple sclerosis
pharmacist
preferences
disease-modifying therapy
disease progression
title_short Assessing Pharmacists' Preferences towards Efficacy Attributes of Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis
title_full Assessing Pharmacists' Preferences towards Efficacy Attributes of Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis
title_fullStr Assessing Pharmacists' Preferences towards Efficacy Attributes of Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis
title_full_unstemmed Assessing Pharmacists' Preferences towards Efficacy Attributes of Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis
title_sort Assessing Pharmacists' Preferences towards Efficacy Attributes of Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis
dc.creator.none.fl_str_mv Martínez-López, Icíar
Maurino, Jorge
Sanmartin-Fenollera, Patricia
Ontanon-Nasarre, Ana
Santiago-Perez, Alejandro
Moya-Carmona, Isabel
Gustavo Garcia-Collado, Carlos
Fernandez-Del Olmo, Raquel
Garcia-Arcelay, Elena
Sarmiento, Monica
Carreno, Agata
Perez-Encinas, Montserrat
author Martínez-López, Icíar
author_facet Martínez-López, Icíar
Maurino, Jorge
Sanmartin-Fenollera, Patricia
Ontanon-Nasarre, Ana
Santiago-Perez, Alejandro
Moya-Carmona, Isabel
Gustavo Garcia-Collado, Carlos
Fernandez-Del Olmo, Raquel
Garcia-Arcelay, Elena
Sarmiento, Monica
Carreno, Agata
Perez-Encinas, Montserrat
author_role author
author2 Maurino, Jorge
Sanmartin-Fenollera, Patricia
Ontanon-Nasarre, Ana
Santiago-Perez, Alejandro
Moya-Carmona, Isabel
Gustavo Garcia-Collado, Carlos
Fernandez-Del Olmo, Raquel
Garcia-Arcelay, Elena
Sarmiento, Monica
Carreno, Agata
Perez-Encinas, Montserrat
author2_role author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv
dc.subject.none.fl_str_mv multiple sclerosis
pharmacist
preferences
disease-modifying therapy
disease progression
topic multiple sclerosis
pharmacist
preferences
disease-modifying therapy
disease progression
description Introduction: Hospital pharmacists are increasingly playing a critical role in the care of patients with multiple sclerosis (MS). However, little is known about their preferences and perspectives towards different attributes of disease-modifying therapies (DMTs). The objective of this research was to assess pharmacists ' preferences for DMT efficacy attributes. Methods: A multicenter, non-interventional, cross-sectional, web-based study was conducted. Preventing relapses, delaying disease progression, controlling radiological activity, and preserving health-related quality of life (HRQoL) and cognition were the attributes selected based on a literature review and a focus group with six hospital pharmacists. Conjoint analysis was used to determine preferences in eight hypothetical treatment scenarios, combining different levels of each attribute and ranking them from most to least preferred. Results: Sixty-five hospital pharmacists completed the study (mean age: 43.5 +/- 7.8 years, 63.1% female, mean years of professional experience: 16.1 +/- 7.4 years). Participants placed the greatest preference on delaying disease progression (35.7%) and preserving HRQoL (21.6%) and cognition (21.6%). Importance was consistent in all groups of pharmacists stratified according to demographic characteristics, experience, research background, and volume of patients seen per year. Conclusions: Understanding which treatment characteristics are meaningful to hospital pharmacists may help to enhance their synergistic role in the multidisciplinary management of patients with MS.
publishDate 2020
dc.date.none.fl_str_mv 2020
2020-06-01
2020
2020-06-01
dc.type.none.fl_str_mv research article
http://purl.org/coar/resource_type/c_2df8fbb1
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://hdl.handle.net/20.500.13003/10487
url https://hdl.handle.net/20.500.13003/10487
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv reponame:Docusalut
instname:Conselleria de Salut i Consum del Govern de les Illes Balears
instname_str Conselleria de Salut i Consum del Govern de les Illes Balears
reponame_str Docusalut
collection Docusalut
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869417719953096704
score 15.812429

Similares en LA Referencia